Yufeng Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yufeng Du has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chunhong Li
Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation The Second Hospital of Dalian Medical University Dalian China
2 shared publications- Jinsong Yan
Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian, China
2 shared publications - Cheng-Tao Zhang
Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China
1 shared publication - Mohammad Arian Hassani
Department of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou district, 116027, Dalian, China
1 shared publication Yikun Liu
School of Public Health Dalian Medical University Dalian China
1 shared publication- Zhijia Zhao
Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation The Second Hospital of Dalian Medical University Dalian China
1 shared publication
Latest Publications
- Open Access
- 29 December 2025
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70450
Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview
Background: Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. Case: In this case report, we present the case of a 40‐year‐old male diagnosed with R/R‐AML who underwent salvage allo‐HSCT. Unfortunately, after 4 months of follow‐up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease. Conclusion: Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post‐HSCT relapsed AML could serve as a valuable reference for treating similar patients.
- 29 December 2025
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70450
Open AccessVenetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview
Background: Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. Case: In this case report, we present the case of a 40‐year‐old male diagnosed with R/R‐AML who underwent salvage allo‐HSCT. Unfortunately, after 4 months of follow‐up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease. Conclusion: Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post‐HSCT relapsed AML could serve as a valuable reference for treating similar patients.
- Open Access
- 10 April 2023
- Published by Taylor & Francis in Hematology
- Vol. 28 (1) , 2198098
The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis
The meta-analysis sought to evaluate the efficacy and safety of a combination of venetoclax (Ven) and azacitidine (AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome...
- 10 April 2023
- Published by Taylor & Francis in Hematology
- Vol. 28 (1) , 2198098
Open AccessThe efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis
The meta-analysis sought to evaluate the efficacy and safety of a combination of venetoclax (Ven) and azacitidine (AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome...